Napatree Capital LLC Sells 1,556 Shares of CVS Health Co. (NYSE:CVS)

Napatree Capital LLC cut its position in CVS Health Co. (NYSE:CVS) by 13.5% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 9,941 shares of the pharmacy operator’s stock after selling 1,556 shares during the quarter. Napatree Capital LLC’s holdings in CVS Health were worth $446,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in CVS. Davis Selected Advisers raised its holdings in CVS Health by 2,998.1% in the fourth quarter. Davis Selected Advisers now owns 11,385,950 shares of the pharmacy operator’s stock worth $511,115,000 after purchasing an additional 11,018,438 shares in the last quarter. Pzena Investment Management LLC raised its holdings in CVS Health by 49.3% in the fourth quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator’s stock worth $880,319,000 after purchasing an additional 6,475,271 shares in the last quarter. Hotchkis & Wiley Capital Management LLC raised its holdings in CVS Health by 34.8% in the third quarter. Hotchkis & Wiley Capital Management LLC now owns 11,897,034 shares of the pharmacy operator’s stock worth $748,085,000 after purchasing an additional 3,071,613 shares in the last quarter. Raymond James Financial Inc. bought a new position in CVS Health in the fourth quarter worth about $116,033,000. Finally, ARGA Investment Management LP raised its holdings in CVS Health by 7,567.7% in the fourth quarter. ARGA Investment Management LP now owns 2,402,901 shares of the pharmacy operator’s stock worth $107,866,000 after purchasing an additional 2,371,563 shares in the last quarter. 80.66% of the stock is currently owned by institutional investors.

Insider Transactions at CVS Health

In related news, SVP James David Clark sold 7,513 shares of the firm’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total transaction of $498,487.55. Following the completion of the transaction, the senior vice president now directly owns 8,394 shares in the company, valued at $556,941.90. This trade represents a 47.23 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Michael F. Mahoney bought 30,000 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were purchased at an average price of $66.70 per share, with a total value of $2,001,000.00. Following the completion of the acquisition, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. This trade represents a 320.65 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.24% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on the stock. Leerink Partners upgraded shares of CVS Health from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $55.00 to $75.00 in a report on Thursday, February 13th. Argus set a $77.00 price objective on shares of CVS Health in a report on Tuesday, February 18th. JPMorgan Chase & Co. upped their price objective on shares of CVS Health from $80.00 to $81.00 and gave the company an “overweight” rating in a report on Tuesday, February 18th. Barclays upped their price objective on shares of CVS Health from $71.00 to $73.00 and gave the company an “overweight” rating in a report on Thursday, February 13th. Finally, Piper Sandler upped their price objective on shares of CVS Health from $72.00 to $74.00 and gave the company an “overweight” rating in a report on Friday. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $70.39.

CVS Health Stock Down 2.1 %

Shares of CVS opened at $67.22 on Friday. CVS Health Co. has a 52-week low of $43.56 and a 52-week high of $80.75. The company has a market capitalization of $84.75 billion, a PE ratio of 18.37, a price-to-earnings-growth ratio of 0.98 and a beta of 0.54. The stock has a fifty day simple moving average of $60.60 and a two-hundred day simple moving average of $57.35. The company has a quick ratio of 0.60, a current ratio of 0.81 and a debt-to-equity ratio of 0.80.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping analysts’ consensus estimates of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. As a group, equities analysts forecast that CVS Health Co. will post 5.89 EPS for the current year.

CVS Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, May 1st. Stockholders of record on Tuesday, April 22nd will be issued a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a dividend yield of 3.96%. The ex-dividend date of this dividend is Tuesday, April 22nd. CVS Health’s dividend payout ratio is presently 72.68%.

CVS Health Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.